Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Redhill Biophrma ADR
(NQ:
RDHL
)
0.3840
+0.0140 (+3.78%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Redhill Biophrma ADR
RedHill Biopharma Ltd. (NASDAQ: RDHL) is One of Wednesday Morning’s Most Active Stocks
November 29, 2023
Via
Investor Brand Network
RedHill Biopharma Ltd Announces RDHL Opaganib Selected by NIH RNCP For Development
February 28, 2023
Via
ACCESSWIRE
RedHill Biopharma Ltd Announces RedHill's RHB-102 Positive MHRA Meeting & MAA Plan
February 16, 2023
Via
ACCESSWIRE
Aegis Capital Corp. Acted as Sole Bookrunner on an $8 Million Underwritten Public Offering for RedHill Biopharma Ltd. (NASDAQ:RDHL)
December 07, 2022
Via
ACCESSWIRE
RedHill Biopharma Ltd Announces Potent Omicron Inhibition with RedHill's Opaganib
April 11, 2022
Oral opaganib's reported potent in vitro activity against Omicron adds to previously observed inhibition of Delta and other SARS-CoV-2 variants of concern that cause COVID-19; Testing conducted by The...
From
RedHill Biopharma Ltd
Via
AccessWire
RedHill Announces Additional Insider Buying
December 15, 2021
RALEIGH, NC and TEL-AVIV, ISRAEL / ACCESSWIRE / December 15, 2021 / RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that...
From
RedHill Biopharma Ltd
Via
AccessWire
Exposures
COVID-19
RedHill Biopharma Ltd Announces Concerning Clarithromycin Rx Rates for H. pylori
December 09, 2021
RedHill Biopharma: Concerning Rates of Clarithromycin Prescribing for H. pylori, Despite Increasing Antibiotic Resistance, Uncovered in New Digestive Diseases & Sciences Publication Despite increasing...
From
RedHill Biopharma Ltd
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
Anxious World Waits As Covid Vaccine Makers Address Omicron Variant
December 07, 2021
Palm Beach, FL – December 7, 2021 – FinancialNewsMedia.com News Commentary There are many unknowns surrounding the new omicron Covid variant; there are early signs it’s more transmissible, but it’s not...
Via
FinancialNewsMedia
Exposures
COVID-19
RedHill Biopharma Ltd - Opaganib MoA Not Impacted by Omicron Mutations
December 06, 2021
Unique Mode of Action Opaganib works by targeting the human host cell rather than the virus itself and is therefore not expected to be impacted by spike protein mutations, providing a strong rationale...
From
RedHill Biopharma Ltd
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
RedHill Biopharma Ltd Announces Talicia: Consistent Efficacy Irrespective of BMI
December 02, 2021
RedHill Biopharma Data Published in GastroHep Shows Consistent Efficacy of Talicia Irrespective of Patient BMI High Body Mass Index and obesity are known risk factors for H. Pylori eradication...
From
RedHill Biopharma Ltd
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
RedHill’s Movantik Added To Medicare Formulary
December 01, 2021
RedHill Biopharma's Movantik® Added as Preferred and Unrestricted Brand To Major National Medicare Formulary Serving Millions of Americans Movantik® approved for inclusion as preferred and unrestricted...
From
RedHill Biopharma Ltd
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
RedHill Reports 3Q/2021 Financial Results
November 30, 2021
RedHill Biopharma Reports Operational Highlights and Third Quarter 2021 Financial Results RedHill Accelerates its Two Advanced COVID-19 Pill Clinical Programs in Light of their Potential Against...
From
RedHill Biopharma Ltd
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
RedHill Biopharma Ltd Announces RedHill: LPI in Part A of RHB-107 P2/3 COVID Study
November 15, 2021
RedHill Biopharma Announces Last Patient Randomized in Part A of Ongoing Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients Recruitment completed for Part A of the Phase...
From
RedHill Biopharma Ltd
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
RedHill Biopharma and South Korea's Kukbo Co. Announce a Strategic Investment of Up To $10 Million in RedHill
November 08, 2021
RedHill received the first tranche of $5 million in a private placement of restricted stock priced at $6.04 per ADS, representing a 20% premium based on the 30 trading days' volume weighted average...
From
RedHill Biopharma Ltd
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
RedHill Biopharma Presents New Talicia(R) and Movantik(R) Data Analyses at ACG 2021
October 25, 2021
Two new analyses evaluate pharmacological and clinical advantages of Talicia® as first-line H. pylori therapy over clarithromycin-based regimens - Two new analyses of Movantik® data evaluate efficacy...
From
RedHill Biopharma Ltd
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
RedHill Biopharma Announces Insider Buying
October 18, 2021
TEL-AVIV, ISRAEL and RALEIGH, NC / ACCESSWIRE / October 18, 2021 / RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that...
From
RedHill Biopharma Ltd
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
RedHill Biopharma Ltd Announces New U.S. Patent for RedHill's Talicia for H.pylori
October 12, 2021
RedHill Biopharma Announces New U.S. Patent Covering Talicia for H. pylori Infection Through 2034 The patent is directed to the Talicia® formulation and pharmaceutical kits for use in the treatment of...
From
RedHill Biopharma Ltd
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
RedHill Biopharma Ltd Announces Talicia(R) added to Medi-Cal CDL
October 06, 2021
RedHill Biopharma's Talicia® added to Medi-Cal Contract Drug List with No Prior Authorization Requirements Addition of Talicia® by Medi-Cal Fee-For-Service (FFS) Contract Drug List (CDL) with no prior...
From
RedHill Biopharma Ltd
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
RedHill Biopharma Reports Further Analysis of Phase 2/3 Data Including a 62% Reduction in Mortality with Oral Opaganib in Moderately Severe COVID-19 Patients
October 04, 2021
62% statistically significant reduction in mortality shown for moderately severe COVID-19 patients group treated with opaganib vs. the placebo-controlled arm (7 deaths in the 117-patient opaganib arm...
From
RedHill Biopharma Ltd
Via
AccessWire
Topics
Death
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Death
Intellectual Property
RHB-107 P2/3 COVID-19 Study South Africa Approval
September 13, 2021
RedHill Biopharma Accelerates Ongoing U.S. Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients with South African Approval The South African Health Products Regulatory...
From
RedHill Biopharma Ltd
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
RedHill Biopharma's Opaganib Demonstrates Significant Decrease of Kidney Fibrosis
September 07, 2021
COVID-19 and long COVID patients are at increased risk of developing kidney damage - Opaganib significantly decreased kidney fibrosis in a preclinical in vivo model - Renal fibrosis is a progressive...
From
RedHill Biopharma Ltd
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
RedHill Biopharma Ltd Announces New Movantik Analyses at PAINWeek
September 07, 2021
RedHill Biopharma Presents Three New Analyses of Movantik Data at PAINWeek 2021 Two new analyses of Movantik® (naloxegol) data evaluated the safety and efficacy of Movantik in a subgroup of patients...
From
RedHill Biopharma Ltd
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
RedHill to Present at HCW & Cantor Conferences
September 02, 2021
RedHill Biopharma to Present at H.C. Wainwright Annual Global Investment and Cantor Global Healthcare Conferences TEL AVIV, ISRAEL and RALEIGH, NC / ACCESSWIRE / September 2, 2021 / RedHill Biopharma...
From
RedHill Biopharma Ltd
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
RedHill Reports Second Quarter 2021 Results
August 26, 2021
- Achieved record quarterly revenues of $21.5 million for Q2/2021, 4.5% increase from Q1/2021 despite challenging market conditions; Cash balance[1] of approximately $71.5 million as of June 30, 2021 -...
From
RedHill Biopharma Ltd
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Supply Chain
Exposures
COVID-19
Intellectual Property
Legal
RedHill Biopharma Ltd Announces RedHill's Opaganib Strong Delta Variant Inhibition
August 26, 2021
RedHill Biopharma's Opaganib Demonstrates Strong Inhibition of COVID-19 Delta Variant Opaganib demonstrated strong inhibition of COVID-19 Delta variant in a human bronchial epithelial cells model,...
From
RedHill Biopharma Ltd
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
RedHill Announces Two New U.S. Patents
August 23, 2021
RedHill Biopharma Announces Two New U.S. Patents Covering Opaganib for Ebola Virus and RHB-104 for Crohn's U.S. patents for opaganib combination for the treatment of Ebola virus disease provides patent...
From
RedHill Biopharma Ltd
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
RedHill Extends Talicia Commercial Coverage
July 20, 2021
RedHill Biopharma Significantly Extends Unrestricted Commercial Coverage for Talicia® with OptumRx Addition of Talicia® by OptumRx significantly extends Commercial patient access to Talicia® through...
From
RedHill Biopharma Ltd
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
RedHill Biopharma Ltd Announces RedHill Biopharma Announces Last Patient Out
July 19, 2021
RedHill Biopharma Announces Last Patient Out for Phase 2/3 COVID-19 Study of Oral Opaganib Patient follow-up completed for the 475-patient global Phase 2/3 study of oral opaganib for severe COVID-19...
From
RedHill Biopharma Ltd
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
35 of the Best Ideas Companies to Present at the Summer Solstice - Best Ideas from the Buy-Side Virtual Investor Conference on June 1-4, 2021
May 27, 2021
RALEIGH, NC / ACCESSWIRE / May 27, 2021 / The Summer Solstice - Best Ideas from the Buy-Side will take place on June 1-4, 2021, where 35 SmallCap, MicroCap and NanoCap public companies will be...
From
MicroCap Rodeo
Via
AccessWire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.